مرعوب قال:
السلام عليكم
السهم هذا Emfp واللى تكلم عنه الاخ مشاري سعره حاليا
1.96 ولا زال يواصل
سبب الارتفاع انفلونزا الطيور
ماشاء الله عليها شركة
ليست لشراء لان وقت الشراء والاحتفاظ بالسهم كان من ايام 30 سنت
للمتابعه
خبر ممتاز والهاي 2.13
وهاي جديد قادم باذن الله ومنها الى الاعلى واتوقع قريبا 2.30 - 2.50
Emergency Filtration Products Reports Successful Test Results Against H9N2 Avian Influenza Strain
Thursday May 25, 2:00 pm ET
HENDERSON, Nev.--(BUSINESS WIRE)--May 25, 2006--Emergency Filtration Products Inc. (EFP) (OTCBB: EMFP - News) today reported that it had received results from an established, BSL-3 (Bio - Safety Level 3) independent testing laboratory that a custom-engineered nanomaterial formulation, licensed to EFP, completely inactivated the H9N2 strain of avian influenza within one minute. The Virucidal Efficacy Test involved a titer of virus with a concentration greater than 6 logs.
ADVERTISEMENT
"The virus tested was of a higher concentration than typically used in this type of challenge," said Douglas K. Beplate, president and CEO, EFP. "An expanded and ongoing testing program of this formulation, and possibly of additional custom-engineered nanomaterials, will be conducted against H9N2 and other pathogens in the coming months."
About Emergency Filtration Products (
http://www.emergencyfiltration.com/)
EFP is an air filtration products manufacturer whose patented 2H Technology(TM) filter system has produced filtration efficiencies of "greater than 99.99%" at a particulate size of 0.027 microns. Its initial products were developed for the medical market: the Vapor Isolation Valve(TM) and RespAide® CPR Isolation Mask used for resuscitation of respiratory/cardiac arrest cases; and the 2H Breathing Circuit Filter for ventilators, respirators and anesthesia circuitry. Each has received FDA approval. The company also markets an Automated External Defibrillator Prep Kit featuring RespAide; and the NanoMask®, a nanotechnology enhanced environmental mask. In addition to filtration products, the company supplies Superstat®, a modified hemostatic collagen, to the U.S. military for surgery and extreme wound care.
Safe Harbor Statement
This release may contain statements that are forward looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. EFP does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. Specifically, as stated above, the announced testing results are part of an ongoing testing program and will need to be confirmed by additional expanded testing currently taking place. Regardless of the results of future tests, the company's sales may be dependent on the success of future marketing campaigns, the results of existing distribution agreements, and both the perceived need for EFP's products and the competitive performance of such products in the marketplace.